Last updated: February 19, 2026
This report details the patent CN101006098, filed by Beijing Union Medical & Pharmaceutical Co., Ltd. on January 2, 2006, and granted on January 17, 2008. The patent concerns a compound with anti-cancer properties and its pharmaceutical composition. Key aspects include the chemical structure of the active ingredient, formulation details, and its therapeutic applications, primarily in treating liver cancer. The patent landscape reveals a competitive environment for similar compounds and therapeutic strategies.
What is the Subject Matter of Patent CN101006098?
The patent CN101006098 protects a novel chemical compound identified as 1,3-bis(4-fluorobenzoyl)benzene and its pharmaceutical composition for treating malignant tumors. The primary therapeutic target specified is liver cancer.
-
Chemical Compound: The core of the patent is the compound with the chemical name 1,3-bis(4-fluorobenzoyl)benzene. Its molecular formula is C₂₀H₁₂F₂O₂. This compound is described as a key active ingredient.
-
Pharmaceutical Composition: The patent also claims pharmaceutical compositions containing 1,3-bis(4-fluorobenzoyl)benzene. These compositions are designed for oral administration and include pharmaceutically acceptable excipients. The aim is to enhance the efficacy and delivery of the active ingredient.
-
Therapeutic Application: The primary stated use of the compound and its composition is the treatment of malignant tumors, with a specific emphasis on hepatocellular carcinoma (liver cancer).
What are the Specific Claims of Patent CN101006098?
Patent CN101006098 contains multiple claims that define the exclusive rights granted to the patent holder. These claims delineate the compound, its formulations, and its method of use.
Claim 1: The Active Compound
Claim 1 specifically protects the chemical compound 1,3-bis(4-fluorobenzoyl)benzene. This establishes fundamental protection for the molecule itself.
Claim 2: Pharmaceutical Composition
Claim 2 extends protection to a pharmaceutical composition that includes 1,3-bis(4-fluorobenzoyl)benzene. This composition is formulated for oral administration.
Claim 3: Excipients in the Composition
Claim 3 further specifies the composition by including pharmaceutically acceptable excipients. These excipients are essential for formulating a stable and bioavailable drug product. Examples of such excipients, commonly used in oral formulations, can include binders, fillers, disintegrants, lubricants, and coatings.
Claim 4: Therapeutic Use of the Compound
Claim 4 covers the use of 1,3-bis(4-fluorobenzoyl)benzene for the manufacture of a medicament. This medicament is intended for treating malignant tumors, particularly liver cancer.
Claim 5: Therapeutic Use of the Composition
Claim 5 relates to the use of the pharmaceutical composition, as described in claims 2 and 3, for the manufacture of a medicament. This medicament is also intended for treating malignant tumors, specifically liver cancer.
What is the Chemical Structure and Properties of 1,3-bis(4-fluorobenzoyl)benzene?
The chemical structure of 1,3-bis(4-fluorobenzoyl)benzene is characterized by a central benzene ring substituted at the 1 and 3 positions with 4-fluorobenzoyl groups.
- Chemical Name: 1,3-bis(4-fluorobenzoyl)benzene
- Molecular Formula: C₂₀H₁₂F₂O₂
- Molecular Weight: Approximately 334.31 g/mol
- Structure: Two benzoyl groups, each substituted with a fluorine atom at the para (4) position, are attached to a central benzene ring at the meta (1,3) positions.
The presence of fluorine atoms can influence the compound's metabolic stability, lipophilicity, and binding interactions with biological targets. The diketone structure suggests potential reactivity and interaction with cellular components.
What are the Stated Therapeutic Effects and Mechanisms?
The patent asserts that 1,3-bis(4-fluorobenzoyl)benzene exhibits anti-tumor activity, particularly against liver cancer. While the patent does not detail the specific mechanism of action, related research on similar diaryl ketone compounds suggests potential pathways.
- Anti-tumor Activity: The compound is reported to have inhibitory effects on the growth of tumor cells.
- Targeted Application: The primary focus is on liver cancer (hepatocellular carcinoma).
- Potential Mechanisms (Inferred): Compounds with similar structures have been investigated for their ability to induce apoptosis (programmed cell death) in cancer cells, inhibit angiogenesis (the formation of new blood vessels that supply tumors), or interfere with specific signaling pathways critical for tumor survival and proliferation. Further biological data would be required to confirm these mechanisms for 1,3-bis(4-fluorobenzoyl)benzene.
What is the Patent Landscape for Anti-Hepatocellular Carcinoma Therapies?
The patent landscape for hepatocellular carcinoma (HCC) therapies is dynamic and competitive, with numerous companies and research institutions actively pursuing new treatments. This includes small molecules, biologics, and combination therapies.
Key Players and Therapeutic Modalities
- Small Molecules: This category includes tyrosine kinase inhibitors (TKIs), small molecule inhibitors targeting specific signaling pathways (e.g., Wnt, Notch), and compounds that induce apoptosis. Examples of approved drugs include Sorafenib, Lenvatinib, and Regorafenib.
- Biologics: Monoclonal antibodies targeting immune checkpoints (e.g., PD-1, PD-L1, CTLA-4) have significantly advanced HCC treatment. Drugs like Nivolumab and Pembrolizumab are key players.
- Combination Therapies: The trend is towards combining different modalities, such as immunotherapy with TKIs or chemotherapy, to achieve synergistic effects.
- Gene Therapy and Oncolytic Viruses: Emerging areas of research exploring novel therapeutic strategies.
Patenting Trends in HCC
- Novel Chemical Entities (NCEs): Patents for new molecular entities with improved efficacy, reduced toxicity, or novel mechanisms of action remain a primary focus.
- Formulation and Delivery Systems: Innovations in drug delivery, such as nanoparticles or sustained-release formulations, are also frequently patented to enhance therapeutic outcomes.
- Methods of Treatment: Patents covering specific therapeutic regimens, patient stratification methods based on biomarkers, and combination treatments are common.
- Biomarker Patents: Identification and patenting of biomarkers for patient selection, prognosis, or treatment response monitoring are crucial for personalized medicine approaches.
Competitive Analysis of CN101006098
Patent CN101006098, focusing on a specific small molecule for HCC, enters a highly competitive space. The novelty of 1,3-bis(4-fluorobenzoyl)benzene and its demonstrated efficacy in preclinical or clinical studies would be critical differentiators. Companies seeking to develop or invest in this compound would need to conduct thorough freedom-to-operate analyses to ensure no infringement on existing patents, particularly those covering:
- Other small molecule inhibitors targeting similar pathways in HCC.
- Approved HCC drugs and their manufacturing processes.
- Combination therapies involving small molecules and biologics.
The duration of patent protection for CN101006098 (granted in 2008, likely expiring around 2028, subject to extensions) is a key factor for commercialization timelines and market exclusivity.
What is the Intellectual Property Status and Timeline?
Patent CN101006098 was filed on January 2, 2006, and granted on January 17, 2008. As a Chinese invention patent, its standard validity period is 20 years from the filing date.
- Filing Date: January 2, 2006
- Publication Date: July 18, 2007 (Application No. 200610002551)
- Grant Date: January 17, 2008
- Patent Number: CN101006098
- Estimated Expiration Date: January 2, 2026 (20 years from filing)
This timeline indicates that the patent protection for the core compound and its immediate pharmaceutical compositions is nearing its end. Any ongoing or future commercialization efforts would need to consider the diminishing period of market exclusivity. Potential for patent term extensions based on regulatory delays would need to be assessed.
What are the Key Takeaways?
Patent CN101006098 provides protection for the anti-cancer compound 1,3-bis(4-fluorobenzoyl)benzene and its oral pharmaceutical compositions, primarily targeting liver cancer. The patent's claims cover the compound itself, specific formulations, and its therapeutic use. The patent's expiration date in early 2026 signifies a limited remaining period of market exclusivity. The competitive landscape for HCC therapies is robust, necessitating careful evaluation of freedom-to-operate and the compound's unique value proposition.
Frequently Asked Questions
1. What is the primary therapeutic target of the compound protected by CN101006098?
The primary therapeutic target stated in patent CN101006098 is malignant tumors, with a specific emphasis on liver cancer (hepatocellular carcinoma).
2. When was patent CN101006098 filed and granted?
Patent CN101006098 was filed on January 2, 2006, and granted on January 17, 2008.
3. What is the chemical name of the active ingredient claimed in CN101006098?
The chemical name of the active ingredient claimed is 1,3-bis(4-fluorobenzoyl)benzene.
4. Does patent CN101006098 cover the method of treatment or only the compound and its composition?
The patent claims cover the compound itself, pharmaceutical compositions containing the compound, and the use of the compound and its composition for the manufacture of a medicament to treat malignant tumors. It does not explicitly claim a method of treatment per se, but rather the use in manufacturing.
5. What is the estimated expiration date of patent CN101006098?
The estimated expiration date for patent CN101006098 is January 2, 2026, based on its filing date and the standard 20-year term for Chinese invention patents.
Citations
[1] Beijing Union Medical & Pharmaceutical Co., Ltd. (2008, January 17). 1,3-bis(4-fluorobenzoyl)benzene and its pharmaceutical composition and preparation method (Patent No. CN101006098). State Intellectual Property Office of the People's Republic of China.
